Disciplina de Neurologia Experimental

Em defesa da administração de doses elevadas de riboflavina associada à eliminação
dos fatores desencadeantes no tratamento da doença de Parkinson do tipo esporádico
Sofrimento emocional e consumo excessivo de carne vermelha
como desencadeantes da doença de Parkinson
Cicero Galli Coimbra e Virgínia Berlanga Campos Junqueira

REFERÊNCIAS BIBLIOGRÁFICAS:

1. Abbot RD, Ross GW, White CR, Sanderson WT, Burchfiel CM, Kashon M, Sharp DS, Masaki KH, Curb JD, Petrovitch H. Environment, life-style, and physical precursors of clinical Parkinson's disease: recent findings from the Honolulu-Asia aging study. J Neurol, 2003; 250(suppl. 3): III-30-III-39.

2. Adelekan DA, Thurnham DI. The influence of riboflavin deficiency on absorption and liver storage of iron in the growing rat. Br J Nutr 1986; 56(1):171-179.

3. Alpert JE, Mischoulon D, Rubenstein GE, Bottonari K, Nierenberg AA, Fava M. Folinic acid (Leucovorin) as an adjunctive treatment for SSRI-refractory depression. Ann Clin Psychiatry 2002;14 (1): 33-38.

4. Anderson BB, Perry GM, Modell CB, Child JA, Mollin DL. Abnormal red-cell metabolism of pyridoxine associated with beta-thalassaemia. Br J Haematol 1979; 41(4):497-507.

5. Anderson BB, Scattoni M, Perry GM, Galvan P, Giuberti M, Buonocore G, Vullo C. Is the flavin-deficient red blood cell common in Maremma, Italy, an important defense against malaria in this area? Am J Human Gen 1994; 55:975-980.

6. Anderson C, Checkoway H, Franklin GM, Beresford S, Smith-Weller T, Swanson PD. Dietary factors in Parkinson's disease: the role of food groups and specific foods. Mov Disord 1999;14(1):21-27.

7. Andrew R, Watson DG, Best SA, Midgley JM, Wenlong H, Petty RK. The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls. Neurochem Res 1993;18(11):1175-1177.

8. Baldereschi M, Di Carlo A, Vanni P, Getti A, Carbonin P, Amaduchi L, Inzitani D. Italian longitudinal study on aging working group.  Life-style related risk factors for Parkinson's disease: a populational study. Acta Neurologica Scand 2003; 106:239-244.

9. Bates CJ. Bioavailability of riboflavin. Eur J Clin Nutr 1997; 51(Suppl 1):S38-S42.

10. Bates CJ. Human riboflavin requirements, and metabolic consequences of deficiency in man and animals. World Rev Nutr Diet 1987; 50:215-265.

11. Beal MF. Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann N Y Acad Sci 2003; 991:120-131.

12. Behari M, Srivastava AK, Das RR, Pandey RM. Risk factors of Parkinson's disease in Indian patients J Neurol Sci 2001; 190 (1-2): 49-55.

13. Bell IR, Edman JS, Morrow FD, Marby DW, Perrone G, Kayne HL, Greenwald M, Cole JO. Brief communication. Vitamin B1, B2, and B6 augmentation of tricyclic antidepressant treatment in geriatric depression with cognitive dysfunction. J Am Coll Nutr 1992a;11 (2): 159-63.

14. Bell IR, Morrow FD, Read M, Berkes S, Perrone G. Low thyroxine levels in female psychiatric inpatients with riboflavin deficiency: implications for folate-dependent methylation. Acta Psychiatr Scand 1992b; 85 (5): 360-363.

15. Ben-Shachar D, Zuk R, Gazawi H, Ljubuncic P. Dopamine toxicity involves mitochondrial complex I inhibition: implications to dopamine-related neuropsychiatric disorders. Biochem Pharmacol 2004; 67 (10): 1965-1974.

16. Ben-Shachar D, Zuk R, Glinka Y. Dopamine neurotoxicity: inhibition of mitochondrial respiration. J Neurochem 1995; 64 (2): 718-723.

17. Betz AL, Ren XD, Ennis SR, Hultquist DE. Riboflavin reduces edema in focal cerebral ischemia. Acta Neurochir Suppl (Wien) 1994; 60: 314-317.

18. Bindoff LA, Birch-Machin M, Cartlidge NEF, Parker JR WD, Turnbull DM. Mitochondrial function in Parkinson`s disease. Lancet 1989; 334, (8653):49.

19. Bindoff LA, Birch-Machin MA, Cartlidge NE, Parker WD, Turnbull DM. Respiratory chain abnormalities in skeletal muscle from patients with Parkinson's disease. J Neurol Sci 1991; 104:203-208.

20. Blass JP, Gibson GE. Abnormality of a thiamine-requiring enzyme in patients with Wernicke-Korsakoff Syndrome. N Engl J Med 1977; 297:1367-1370.

21. Blin O, Desnuelle C, Rascol O. Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson's disease and multiple system atrophy. J Neurol Sci 1994; 125 (1): 95-101.

22. Bolander-Gouaille C, Bottiglieri T. Homocysteine related vitamins and neuropsychiatric disorders. Paris, Springer, 2003.

23. Boyer R, Grabill T, Petrovich R. Reactive release of ferritin iron: a kinetic assay. Anal Biochem 1988; 174: 17-22.

24. Bradley WG, Daroff RB, Fenichel GM, Marsden CD. Diagnosis of Neurological Disease. In: Bradley WG, Daroff RB, Fenichel GM, Marsden CD (ed). Neurology in Clinical Practice. Volume I: Principles of Diagnosis and Management. Boston, Butterworth-Heinemann, 2000, pag 3-8.

25. Brooks DJ, Doder M. Depression in Parkinson's disease. Curr Opin Neurol 2001; 14 (4): 465-470.

26. Calingasan NY, Sheu K-FR, Baker H, Gandy SE, Gibson GE. Thiamine deficiency as a model of selective neurodegeneration with chronic oxidative stress. In: Fiskum G (ed): Neuroderenerative Diseases. Molecular and Cellular Mechanisms and Therapeutic Advances. New York, Plenum Press, 1991, pp 193-201.

27. Cardellach F, Martí MJ, Fernández-Solá J, Marín C, Hoek J B, Tolosa E, Urbano-Márquez A. Mitochondrial respiratory chain activity in skeletal muscle from patients with Parkinson's disease. Neurology 1993; 43 (11): 2258-2262.

28. Carney MW, Ravindran A, Rinsler MG, Williams DG. Thiamine, riboflavin and pyridoxine deficiency in psychiatric in-patients. Br J Psychiatry 1982; 141: 271-272.

29. Christensen HN. Riboflavin can protect tissue from oxidative injury. Nutr Rev 1993; 51 (5): 149-150.

30. Coimbra CG, Junqueira VBC. High doses of riboflavin and dietary elimination of red meat promotes recovery of some motor functions of Parkinson's disease patients.  Braz J Med Biol Res 2003; 36:1409-1417.

31. Cohen G. Monoamine oxidase and oxidative stress at dopaminergic synapses. J Neural Transm Suppl 1990; 32: 229-238.

32. Coppen A, Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial. J Affect Disord 2000; 60 (2): 121-30.

33. Coyle D, Barbeau M, Guttman M, Baladi J-F. The economic evaluation of pharmacotherapies for Parkinson's disease. Parkinsonism Relat Disord 2003; 9 (5): 301-307.

34. Cummings JL. Depression and Parkinson's disease: a review. Am J Psychiatry 1992; 149 (4): 443-454.

35. Curzon G. Metals and melanins in the extrapyramidal centers.  Pharmacology & Therapeutics Part B: General and Systematic Pharmacology 1975; 1 (4): 673-684.

36. Cuttle L, Munns AJ, Hogg NA, Scott JR, Hooper WD, Dickinson RG, Gillam EM. Phenytoin metabolism by human cytochrome P450: involvement of P450 3A and 2C forms in secondary metabolism and drug-protein adduct formation. Drug Metab Dispos 2000; 28 (8): 945-950.

37. Dexter DT, Sian J, Rose S, Hindmarsh JG, Mann VM, Cooper JM, Wells FR, Daniel SE, Lees AJ, Schapira AH.  Indices of oxidative stress and mitochondrial function with incidental Lewy body disease.  Ann Neurol 1994; 35:38-44.

38. Dodel RC, Singer M, Kohne-Volland R, Szucs T, Rathay B, Scholz E, Oertel WH. The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis. Pharmacoeconomics 1998; 14(3):299-312.

39. Drachman DA. Occam's razor, geriatric syndromes, and the dizzy patient. Ann Intern Med 2000;132(5):403-404.

40. Edmondson DE, Binda C, Mattevi A. The FAD Binding Sites of Human Monoamine Oxidases A and B. NeuroToxicology 2004; 25 (1-2): 63-72.

41. Elkon H, Melamed E, Offen D. 6-Hydroxydopamine increases ubiquitin-conjugates and protein degradation: implications for the pathogenesis of Parkinson's disease. Cell Mol Neurobiol 2001; 21 (6): 771-781.

42. Factor SA, Weiner WJ, Hefti F. Acetaminophen metabolism by cytochrome P450 monooxygenases in Parkinson's disease. Ann Neurol. 1989; 26 (2): 286-288.

43. Fahn S. Parkinsonism. In: Rowland LP (ed) Merritt's Neurology. Philadelphia, Lippincott Williams & Wilkins, 2000, p 679-693.

44. Fastovsky DE, Weishampel DB. The Evolution and Extinction of the Dinosaurs. Melbourne, Cambridge University Press, 1996, p 437.

45. Ferrari MD, Peeters EA, Haan J, Roos RA, Vermey P, de Wolff FA, Buruma OJ. Cytochrome P450 and Parkinson's disease. Poor parahydroxylation of phenytoin. J Neurol Sci 1990; 96 (2-3): 153-157.

46. Ferraz HB, Quagliato E. Parkinson Em Foco. São Paulo, Phoenix Comunicação Integrada (Behringer Ingelheim). Edição 1 - abril, 2004.

47. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature 2000; 408 (6809): 239-247.

48. Fiszer U. Does Parkinson's disease have an immunological basis? The evidence and its therapeutic implications. BioDrugs 2001; 15 (6): 351-355.

49. Gao HM, Liu B, Zhang W, Hong JS. Novel anti-inflammatory therapy for Parkinson's disease. Trends Pharmacol Sci 2003; 24(8):395-401.

50. Garcion E, Wion_Barbot N, Montero_Menei CN, Berger F, Wion D. New clues about vitamin D functions in the nervous system. Trends Endocrinol Metab 2002; 13: 100-105.

51. Gibb WR. Melanin, tyrosine hydroxylase, calbindin and substance P in the human midbrain and substantia nigra in relation to nigrostriatal projections and differential neuronal susceptibility in Parkinson's disease. Brain Res 1992; 581: 283 291.

52. Gibberd FB, Simmonds JP. Neurological disease in ex-Far-East prisoners of war. Lancet 1999; 354 (9196): 2116-2118.

53. Goddard JG, Gower JD, Green CJ. A chelator is required for microsomal lipid peroxidation following reductive ferritin-iron mobilisation. Free Radic Res Commun 1992;17(3):177-185.

54. Godfrey P, Crellin R, Toone BK, Flynn TG, Carney MW, Laundy M, Chanarin I, Bottiglieri T, Reynolds EH. Enhancement of recovery from psychiatric illness by methylfolate. Br J Psychiatry 1992; 161: 126-127.

55. Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, Giladi N, Holloway RG, Moore CG, Wenning GK, Yahr MD, Seidl L; Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord. 2004; 19 (9): 1020-1028.

56. Golbe LI, Farrel TM, Davis PH. Case-control study of early life dietary factors in Parkinson's disease. Arch Neurol, 1988; 45:350-353.

57. Goloboff PA. Parsimony, likelihood, and simplicity. Cladistics 2003; 19 (2): 91-103.

58. Gorell J, Johnson C, Rybicki B, Peterson E. A population-based case-control study of nutrient intake in Parkinson's disease. Neurology 1997;48:A298.

59. Götz ME, Double K, Gerlach M, Youdim MB, Riederer P.The relevance of iron in the pathogenesis of Parkinson's disease. Ann N Y Acad Sci 2004; 1012: 193-208.

60. Graham DG. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Molec Pharmac 1978; 14 ():633-643.

61. Hack MH, Helmy FM. The melanins and lipofuscin. Comp Biochem Physiol Part B: Biochem Mol Biol 1983; 76 (3): 399-407.

62. Hara T, Taniguchi M. Abnormal NADPH-cytochrome P-450 reductase in the liver microsomes of riboflavin-deficient rats. Biochem Biophys Res Commun 1982;104(2):394-401.

63. Hara T, Taniguchi M. Relationship between changes in properties and contents of riboflavin derivatives of NADPH-cytochrome P-450 reductase in the liver microsomes of riboflavin-deficient rats. J Biochem (Tokyo) 1985; 97(2):473-482.

64. Hastings TG. Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J Neurochem 1995; 64 (): 919-924.

65. Hellenbrand W, Seidler A, Boeing H, Robra BP, Vieregge P, Nischan P, Joerg J, Oertel WH, Schneider E, Ulm G. Diet and Parkinson's disease. I: A possible role for the past intake of specific foods and food groups. Results from a self-administered food-frequency questionnaire in a case-control study. Neurology 1996; 47:636-643.

66. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17 (5): 427-442.

67. Hoorn RKJ, Plikweert JP, Westerink D. Vitamin B-1, B-2 and B-6 deficiencies in geriatric patients, measured by coenzyme stimulation of enzyme activities. Clin Chim Acta 1975; 61:151-162.

68. Hornykiewicz O, Kish SJ. Biochemical pathophysiology of Parkinson's disease. Adv Neurol 1987; 45: 19-34.

69. Hughes TA, Ross HF, Mindham RH, Spokes EG. Mortality in Parkinson's disease and its association with dementia and depression. Acta Neurol Scand 2004;110 (2): 118-123.

70. Hustad S, McKinley MC, McNulty H, Schneede J, Strain JJ, Scott JM, Ueland PM. Riboflavin, flavin mononucleotide, and flavin adenine dinucleotide in human plasma and erythrocytes at baseline and after low-dose riboflavin supplementation. Clin Chem 2002; 48:1571-1577.

71. Hustad S, Ueland PM, Vollset SE, Zhang Y, Bjorke-Monsen AL, Schneede J. Riboflavin as a determinant of plasma total homocysteine: effect modification by the methylenetetrahydrofolate reductase C677T polymorphism. Clin Chem 2000; 46 (8 Pt 1): 1065-1071.

72. Ikebe S, Tanaka M, Ohno K, Sato W, Hattori K, Kondo T, Mizuno Y, Ozawa T. Increase of deleted mitochondrial DNA in the striatum in Parkinson's disease and senescence. Biochem Biophys Res Commun 1990; 170(3):1044-1048.

73. Jameson GN, Jameson RF, Linert W. New insights into iron release from ferritin: direct observation of the neurotoxin 6-hydroxydopamine entering ferritin and reaching redox equilibrium with the iron core. Org Biomol Chem 2004; 2 (16): 2346-2351.

74. Jenner P, Schapira AH, Marsden CD. New insights into the cause of Parkinson's disease. Neurology 1992; 42 (12): 2241-2250.

75. Johnson CC, Gorell JM, Rybicki BA, Sanders K, Peterson EL. Adult nutrient intake as a risk factor for Parkinson's disease. Int J Epidemiol 1999; 28(6):1102-1109.

76. Kaasinen V, Nurmi E, Bergman J, Eskola O, Solin O, Sonninen P, Rinne JO. Personality traits and brain dopaminergic function in Parkinson's disease. Proc Natl Acad Sci U S A 2001; 98 (23): 13272-13277.

77. Kalra J, Rajput AH, Mantha SV, Prasad K. Serum antioxidant enzyme activity in Parkinson's disease. Mol Cell Biochem 1992; 110(2):165-168.

78. Kastner A, Hirsch EC, Lejeune O, Javoy-Agid F, Rascol O, Agid Y. Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content? J Neurochem 1992; 59 (3): 1080 1089.

79. Kaur D, Andersen J. Does cellular iron dysregulation play a causative role in Parkinson's disease? Ageing Res Rev 2004; 3 (3): 327-343.

80. Korytowski WST, Kalysnaraman B, Sealy RC. Tyrosine-catalyzed oxidation of dopa and related catechol(amine)s: a kinetic electron spin resonance investigation using stabilization and spin label oximetry. Biochim Biophys Acta 1987; 924 (): 383-392.

81. Kotegawa M, Sugiyama M, Haramaki N. Protective effects of riboflavin and its derivatives against ischemic reperfused damage of rat heart. Biochem Mol Biol Int 1994; 34 (4): 685-691.

82. Kozik A, Korytowski W, Sarna T, Bloom AS. Interactions of flavins with melanin Studies on equilibrium binding of riboflavin to DOPA-melanin and some spectroscopic characteristics of flavin-melanin complex Biophys Chem 1990; 38 (1-2): 39-48.

83. Kurth MC, Kurth JH. Variant cytochrome P450 CYP2D6 allelic frequencies in Parkinson's disease. Am J Med Genet 1993; 48 (3): 166-168.

84. LaVoie MJ, Hastings TG. Peroxynitrite- and nitrate-induced oxidation of dopamine: implications for nitric oxide in dopaminergic cell loss. J Neurochem 1999; 73 ():2546-2554.

85. Lee GR, Herbert V. Nutritional factors in the production and function of erythrocytes.  In: Lee R, Foester J, Lukens J, Paraskevas F, Rodgers GM (ed) Wintrobe's Clinical Hematology (10th ed) vol I, Philadelphia, Lippincott Williams & Wilkins, 1998, pp 228-266.

86. Leentjens AF, Van den Akker M, Metsemakers JF, Lousberg R, Verhey FR. Higher incidence of depression preceding the onset of Parkinson's disease: a register study. Mov Disord 2003;18 (4): 414-418.

87. LePen C, Wait S, Moutard-Martin F, Dujardin M, Ziegler M. Cost of illness and disease severity in a cohort of French patients with Parkinson's disease. Pharmacoeconomics 1999;16(1):59-69.

88. Lestienne P, Nelson J, Riederer P, Jellinger K, Reichmann H. Normal mitochondrial genome in brain from patients with Parkinson's disease and complex I defect. J Neurochem 1990; 55(5):1810-1812.

89. Linert W, Herlinger E, Jameson RF, Kienzl E, Jellinger K, Youdim MB. Dopamine, 6-hydroxydopamine, iron, and dioxygen--their mutual interactions and possible implication in the development of Parkinson's disease. Biochim Biophys Acta 1996; 1316 (3): 160-168.

90. Linert W, Jameson GN. Redox reactions of neurotransmitters possibly involved in the progression of Parkinson's Disease. J Inorg Biochem 2000; 79 (1-4): 319-326.

91. Lo Re V 3rd, Bellini LM. William of Occam and Occam's razor. Ann Intern Med 2002;136(8):634-635.

92. Logroscino G, Marder K, Cote L, Tang MX, Shea S, Mayeux R. Dietary lipids and antioxidants in Parkinson's disease: a population-based, case-control study. Ann Neurol 1996;39(1):89-94.

93. Logroscino G, Marder K, Graziano J, Freyer G, Slavkovich V, Lojacono N, Cote L, Mayeux R. Dietary iron, animal fats, and risk of Parkinson's disease. Mov Disord 1998;13 (Suppl 1):13-16.

94. Maker HS, Weiss C, Silides DJ, Cohen G. Coupling of dopamine oxidation (monoamine oxidase activity) to glutathione oxidation via the generation of hydrogen peroxide in rat brain homogenates. J Neurochem 1981; 36 (2): 589-593.

95. Marder K, Logroscino G, Tang MX, Graziano J, Cote L, Louis E, Alfaro B, Mejia H, Slavkovich V, Mayeux R Systemic iron metabolism and mortality from Parkinson's disease. Neurology 1998; 50 (4): 1138-40.

96. Marttila, R J; Rinne, U K. Progression and survival in Parkinson's disease Acta Neurol Scand, Suppl 1991; 136:24-28.

97. Massey V. The chemical and biological versatility of riboflavin. Biochem Soc Trans 2000; 28 (4): 283-296.

98. Mathieu C, Adorini L. The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. Trends Mol Med 2002; 8 (4): 174-179.

99. Mawrin C, Kirches E, Krause G, Schneider-Stock R, Bogerts B, Vorwerk CK, Dietzmann K. Region-specific analysis of mitochondrial DNA deletions in neurodegenerative disorders in humans. Neurosci Lett 2004; 357 (2): 111-114.

100. McGeer PL, McGeer EG. Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord 2004; 10 (Suppl 1): S3-S7.

101. Mizuno Y, Ohta S, Tanaka M, Takamiya S, Suzuki K, Sato T, Oya H, Ozawa T, Kagawa Y. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease.  Biochem Biophys Res Commun 1989; 163: 1450-1455.

102. Monks TJ, Hanzlik RP, Cohen GM, Ross D, Graham DG. Quinone chemistry and toxicity. Toxicol Appl Pharmac 1992; 112 (): 2-16.

103. Monteiro H, Winterbourn C. The superoxide-dependent transfer of iron from ferritin to transferrin and lactoferrin. Biochem J 1988; 256(3): 923-928.

104. Mytilineou C, Werner P, Molinari S, Di Rocco A, Cohen G, Yahr MD. Impaired oxidative decarboxylation of pyruvate in fibroblasts from patients with Parkinson's disease. J Neural Transm Park Dis Dement Sect 1994; 8: 223-228.

105. Nelson DL, Cox MM. Lehninger Principles of Biochemistry. New York, Worth Publishers, 2000.

106. Nowak A. Dynamical minimalism: why less is more in psychology. Pers Soc Psychol Rev 2004; 8 (2): 183-192.

107. Obika M. Reversible binding of riboflavin and pteridines to melanin in vitro. Comp Biochem Physiol B 1976; 53 (4): 521-523.

108. Orth M, Schapira AHV. Mitochondrial involvement in Parkinson's disease. Neurochem Intern 2002; 40 (6): 533-541.

109. Page WF, Tanner CM. Parkinson's disease and motor-neuron disease in former prisoners-of-war. Lancet 2000; 355 (9206): 843.

110. Parker WD, Boyson SJ, Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 1989; 26: 719-723.

111. Passeri M, Cucinotta D, Abate G, Senin U, Ventura A, Stramba Badiale M, Diana R, La Greca P, Le Grazie C. Oral 5'-methyltetrahydrofolic acid in senile organic mental disorders with depression: results of a double-blind multicenter study. Aging (Milano) 1993; 5 (1): 63-71.

112. Peeters EAJ, Bloem BR, Kuiper MA, Vermeij P, de Wolff FA, Wolters EC, Roos RAC, Ferrari MD. Phenytoin parahydroxylation is not impaired in patients with young-onset Parkinson's disease. Clin Neurol Neurosurg 1994; 96 (4): 296-299.

113. Pereira AC, Schettert IT, Morandini Filho AA, Guerra-Shinohara EM, Krieger JE. Methylenetetrahydrofolate reductase (MTHFR) c677t gene variant modulates the homocysteine folate correlation in a mild folate-deficient population. Clin Chim Acta 2004; 340 (1-2): 99-105.

114. Perese DA, Ulman J, Viola J, Ewing SE, Bankiewicz KS. A 6-hydroxydopamine-induced selective parkinsonian rat model. Brain Res 1989; 494 (2 ): 285-293.

115. Plante-Bordeneuve V, Davis MB, Maraganore DM, Marsden CD, Harding AE. Debrisoquine hydroxylase gene polymorphism in familial Parkinson's disease. J Neurol Neurosurg Psychiatry 1994; 57 (8): 911-913.

116. Poewe W, Seppi K. Treatment options for depression and psychosis in Parkinson's disease. J Neurol 2001;248 (Suppl 3):III12-III21.

117. Poewe W. Psychosis in Parkinson's disease. Mov Disord 2003; 18 (Suppl 6):S80-S87.

118. Poewe W. The Sydney multicentre study of Parkinson's disease. J Neurol Neurosurg Psychiatry 1999;67(3):280-281.

119. Poewe WH, Wenning GK. The natural history of Parkinson's disease. Ann Neurol 1998; 44(3 Suppl 1):S1-S9.

120. Polakiewicz B. Patentes, Tecnologia e Ética. Revista de Graduação da Engenharia Química. ANO V No. 9 Jan-Jun 2002. ISSN 1516-5469.

121. Powers HJ, Bates CJ, Duerden JM. Effects of riboflavin deficiency in rats on some aspects of iron metabolism. Int J Vitam Nutr Res 1983; 53 (4): 371-6.

122. Powers HJ, Weaver LT, Austin S, Wright AJ, Fairweather-Tait SJ. Riboflavin deficiency in the rat: effects on iron utilization and loss. Br J Nutr 1991; 65(3):487-496.

123. Powers HJ. Experiment to determine the effect of riboflavin deficiency at weaning on iron economy and heme synthesis. Ann Nutr Metab 1985; 29 (5): 261-266.

124. Powers KM, Smith-Weller T, Franklin GM, Longstreth WT Jr, Swanson PD, Checkoway H. Parkinson's disease risks associated with dietary iron, manganese, and other nutrient intakes. Neurology 2003; 60(11):1761-1766.

125. Rabey JM, Bass H, Bonuccelli U, Brooks D, Klotz P, Korczyn AD, Kraus P, Martinez-Martin P, Morrish P, Van Sauten W, Van Hilten B. Evaluation of the Short Parkinson's Evaluation Scale: a new friendly scale for the evaluation of Parkinson's disease in clinical drug trials. Clin Neuropharmacol 1997; 20 (4): 322-337.

126. Rabey JM, Klein C, Molochnikov A, Van Hilten B, Krauss P, Bonuccelli U. Comparison of the Unified Parkinson's Disease Rating Scale and the Short Parkinson's Evaluation Scale in patients with Parkinson's disease after levodopa loading. Clin Neuropharmacol 2002; 25:83-88.

127. Rabinovic AD, Hastings TG. Role of endogenous glutathione in the oxidation of dopamine. J Neurochem 1998; 71 (5): 2071-2078.

128. Rabinovic AD, Lewis DA, Hastings TG. Role of oxidative changes in the degeneration of dopamine terminals after injection of neurotoxic levels of dopamine. Neuroscience 2000;101 (1): 67-76.

129. Riederer P, Sofic E, Raush WD, Schmidt B, Reynolds GP, Jellinger K, Youdim MB.  Transition metals, ferritin, glutathione and ascorbic acid in parkinsonian brains. J Neurochem 1989; 52:515-520.

130. Riedl AG, Watts PM, Jenner P, Marsden CD. P450 enzymes and Parkinson's disease: the story so far. Mov Disord 1998; 13 (2): 212-220.

131. Riobo NA, Schopfer FJ, Boveris AD, Cadenas E, Poderoso JJ. The reaction of nitric oxide with 6-hydroxydopamine: implications for Parkinson's disease. Free Radic Biol Med 2002; 32(2):115-121.

132. Rosei MA, Blarzino C, Foppoli C, Mosca L, Coccia R. Lipoxygenase-catalyzed oxidation of catecholamines. Biochem. Biophys. Res Commun 1994; 200 (): 344-350.

133. Rowland LP. Sings and symptoms in neurologic diagnosis. In: Rowland LP (ed) Merritt's Neurology. Philadelphia, Lippincott Williams & Wilkins, 2000, p 50-52.

134. Rubenstein LM, Chrischilles EA. Voelker MD. The impact of Parkinson's disease on health status, health expenditures, and productivity. Estimates from the National Medical Expenditure Survey. Pharmacoeconomics 1997; 12(4):486-498.

135. Rybicki BA, Johnson CC, Peterson EL, Kortsha GX, Gorell JM. A family history of Parkinson's disease and its effect on other PD risk factors. Neuroepidemiology 1999;18(5):270-278.

136. Santamaria J, Tolosa E Valles A. Parkinson's disease with depression: a possible subgroup of idiopathic parkinsonism. Neurology 1986; 36 (8): 1130-1133.

137. Santamaria J, Tolosa ES, Valles A, Bayes A, Blesa R, Masana J. Mental depression in untreated Parkinson's disease of recent onset. Adv Neurol 1987; 45: 443-446.

138. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 1990a; 54: 823-827.

139. Schapira AH, Holt IJ, Sweeney M, Harding AE, Jenner P, Marsden CD. Mitochondrial DNA analysis in Parkinson's disease. Mov Disord 1990b; 5(4):294-297.

140. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 1998; 50: 466-470.

141. Schoenen J, Lenaerts M, Bastings E. High-dose riboflavin as a prophylactic treatment of migraine: results of an open pilot study. Cephalalgia 1994; 14: 328-329.

142. Schrag A. Psychiatric aspects of Parkinson's disease--an update. J Neurol 2004; 251(7):795-804.

143. Segatto J. Mal de Parkinson aumenta com envelhecimento da população. Ciência, Tecnologia e Meio Ambiente. Agência Brasil - RadioBrás. http://www.radiobras.gov.br/ct/2002/notas_180102.htm

144. Shahi GS, Das NP, Moochhala SM. Parkinson's disease and cytochrome P450: a possible link? Med Hypotheses 1990; 32 (4): 277-282.

145. Shoffner JM, Watts RL, Juncos JL, Torroni A, Wallace DC. Mitochondrial oxidative phosphorylation defects in Parkinson's disease. Ann Neurol 1991; 30(3):332-339.

146. Siderowf AD, Holloway RG, Stern MB. Cost-effectiveness analysis in Parkinson's disease: determining the value of interventions. Movement Disord 2000; 15 (3):439-445.

147. Sirivech S, Driskell J, Frieden E. NADH-FMN oxidoreductase activity and iron content of organs from riboflavin and iron-deficient rats. J Nutr 1977; 107 (5): 739-745.

148. Smith AD, Castro SL, Zigmond MJ. Stress-induced Parkinson's disease: a working hypothesis. Physiol Behav 2002; 77 (4-5): 527-531.

149. Smythies J, Galzigna L. The oxidative metabolism of catecholamines in the brain: a review. Biochim Biophys Acta - General Subjects 1998; 1380 (2): 159-162.

150. Spina MB, Cohen G. Hydrogen peroxide production in dopamine neurons. Basic Life Sci 1988; 49: 1011-1014.

151. Steier M, Lopez R, Cooperman JM. Riboflavin deficiency in infants and children with heart disease. Am Heart J 1976; 92(2):139-143.

152. Steiger MJ, Lledo P, Quinn NP, Marsden CD, Turner P, Jenner PG. Debrisoquine hydroxylation in Parkinson's disease. Acta Neurol Scand 1992; 86 (2): 159-64.

153. Steventon GB, Sturman S, Waring RH, Williams AC. A review of xenobiotic metabolism enzymes in Parkinson's disease and motor neuron disease. Drug Metabol Drug Interact 2001; 18 (2): 79-98.

154. Sulzer D, Bogulavsky J, Larsen KE, Behr G, Karatekin E, Kleinman MH, Turro N, Krantz D, Edwards RH, Greene LA, Zecca L. Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc Natl Acad Sci U S A 2000; 97 (22): 11869-11874.

155. Takenouchi K, Aso K, Utsumi K. Participation of thiamine and riboflavin in the formation of tyrosine melanin. J Vitaminol (Kyoto) 1960 10; 6: 308-320.

156. Tanner CM, Ben-Shlomo Y. Epidemiology of Parkinson's disease. Adv Neurol 1999; 80:153-159.

157. Tanner CM, Chen B, Wang B et al. Environmental factors in Parkinson's disease: a case control study in China. Neurology 1989; 39 (): 660-664.

158. Tanner CM, Goldman SM, Ross GW. Etiology of Parkinson's disease. In: Jankovik JJ, Tolosa E (Editors), Parkinson's Disease and Movement Disorders. Philadelphia, PA, USA, Lippincott Williams & Wilkins, 2002.

159. Tanner CM. Epidemiological clues to the cause of Parkinson's disease. In: Marsden CD, Fahn S (ed), Movement Disorders 3. Oxford, UK, Butterworth-Heinemann, 1994, pp 124-146.

160. Tief K, Schmidt A, Beermann F. New evidence for presence of tyrosinase in substantia nigra, forebrain and midbrain. Brain Res Mol Brain Res 1998; 53 (1-2): 307-310.

161. Topham R, Goger M, Pearce K, Schultz P. The mobilization of ferritin iron by liver cytosol. A comparison of xanthine and NADH as reducing substrates. Biochem J 1989; 261 (1): 137-143.

162. Tsai CH, Lo SK, See LC, Chen HZ, Chen RS, Weng YH, Chang FC, Lu CS. Environmental risk factors of young onset Parkinson's disease: a case control study. Clin Neurol Neurosurg 2002; 104:328-333.

163. Vogel HP. Symptoms of depression in Parkinson's disease. Pharmacopsychiatria 1982; 15 (6): 192-196.

164. Wang M, Roberts DL, Paschke R, Shea TM, Masters BS, Kim JJ. Three-dimensional structure of NADPH-cytochrome P450 reductase: prototype for FMN- and FAD-containing enzymes. Proc Natl Acad Sci U S A 1997; 94 (16): 8411-8416.

165. Wersinger C, Sidhu A. Inflammation and Parkinson's disease. Curr Drug Targets Inflamm Allergy 2002; 1 (3): 221-242.

166. Whetten-Goldstein K, Sloan F, Kulas E, Cutson T, Schenkman M. The burden of Parkinson's disease on society, family, and the individual. J Am Geriatr Soc 1997; 45(7):844-849.

167. Williams A, Steventon G, Sturman S, Waring R. Xenobiotic enzyme profiles and Parkinson's disease. Neurology 1991; 41 (5 Suppl 2): 29-32;

168. Wolozin B, Golts N. Iron and Parkinson's disease. Neuroscientist 2002; 8 (1): 22-32.

169. Xu Y, Stokes AH, Freeman WM, Kumer SC, Vogt BA, Vrana KE. Tyrosinase mRNA is expressed in human substantia nigra. Brain Res Mol Brain Res 1997; 45 (1): 159-162.

170. Yoshida T, Migita CT. Mechanism of heme degradation by heme oxygenase. J Inorg Biochem 2000; 82 (1-4): 33-41.

171. Yoshida T, Tanaka M, Sotomatsu A, Hirai S. Activated microglia cause superoxide-mediated release of iron from ferritin. Neurosci Lett 1995; 190 (1): 21-24.

172. Zaman Z, Verwilghen RL. Effect of riboflavin deficiency on activity of NADH-FMN oxidoreductase (ferriductase) and iron content of rat liver. Biochem Soc Trans 1977; 5 (1): 306-308.

173. Zecca L, Zucca FA, Wilms H, Sulzer D. Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics. Trends Neurosci 2003; 26 (11): 578-580.

174. Zempleni J, Galloway JR, McCormick DB. Pharmacokinetics of orally and intravenously administered riboflavin in health humans. Am J Clin Nutr 1996; 63:54-66.

175. Zucca FA, Giaveri G, Gallorini M, Albertini A, Toscani M, Pezzoli G, Lucius R, Wilms H, Sulzer D, Ito S, Wakamatsu K, Zecca L. The neuromelanin of human substantia nigra: physiological and pathogenic aspects. Pigment Cell Res 2004; 17 (6): 610-617.

Home

Voltar para o índice